Precipio (NASDAQ:PRPO) Issues Quarterly Earnings Results

Precipio (NASDAQ:PRPO) issued its earnings results on Friday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, Zacks reports. Precipio had a negative net margin of 8.48% and a negative return on equity of 15.00%.

Precipio Stock Down 0.7%

Shares of PRPO traded down $0.15 during mid-day trading on Friday, reaching $19.38. 17,437 shares of the stock traded hands, compared to its average volume of 12,666. The stock has a fifty day simple moving average of $19.45 and a 200 day simple moving average of $14.62. Precipio has a 12-month low of $3.90 and a 12-month high of $22.38. The company has a quick ratio of 0.69, a current ratio of 0.93 and a debt-to-equity ratio of 0.05. The firm has a market cap of $31.39 million, a price-to-earnings ratio of -16.28 and a beta of 1.14.

Analyst Ratings Changes

Several equities analysts have weighed in on PRPO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Precipio to a “buy” rating in a report on Friday, September 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Precipio has a consensus rating of “Sell”.

About Precipio

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.